NASDAQ : SLDB
Solid Biosciences Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 6.39 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 685.17M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 628.34M |
| Enterprise Value | 270.82M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 107.23M |
| Shares Outstanding | 107.23M |
| Shares Change (YoY) | +80.98% |
| Shares Change (QoQ) | +30.85% |
| Owned by Insiders (%) | 0.92% |
| Owned by Institutions (%) | 69.84% |
| Float | 64.80M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.74 |
| P/TBV Ratio | 1.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 13.82 |
| Quick Ratio | 13.21 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -65.50% |
| Return on Assets (ROA) | -36.38% |
| Return on Invested Capital (ROIC) | -39.25% |
| Return on Capital Employed (ROCE) | -54.12% |
| Weighted Average Cost of Capital (WACC) | 17.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.71M |
| Employee Count | 121 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.47 |
| 52-Week Price Change | +13.17% |
| 50-Day Moving Average | 7.75 |
| 200-Day Moving Average | 7.66 |
| Relative Strength Index (RSI) | 41.09 |
| Average Volume (20 Days) | 1,289,514 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 12.30M |
| Short Previous Month | 12.73M |
| Short % of Shares Out | 11.47% |
| Short % of Float | 18.98% |
| Short Ratio (days to cover) | 7.88 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -212.15M |
| Pretax Income | -207.10M |
| Net Income | -207.10M |
| EBITDA | -210.52M |
| EBIT | -212.15M |
| Earnings Per Share (EPS) | -$1.87 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 377.68M |
| Total Debt | 20.16M |
| Net Cash | 357.52M |
| Net Cash Per Share | $3.33 |
| Equity (Book Value) | 374.08M |
| Book Value Per Share | 3.56 |
| Working Capital | 366.52M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -186.84M |
| Capital Expenditures | -965,000 |
| Depreciation & Amortization | 1.63M |
| Net Borrowing | -446,000 |
| Free Cash Flow | -187.81M |
| FCF Per Share | -$1.75 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -80.98% |
| Shareholder Yield | -80.98% |
| Earnings Yield | -31.91% |
| FCF Yield | -28.25% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $18.71 |
| Price Target Difference | 219.28% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 28, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |